SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)

被引：0
|
作者：
Barkmanova, Jaroslava [1 ]
Petruzelka, Lubos [1 ,2 ]
Sedlackova, Eva [1 ,2 ]
Vocka, Michal [1 ,2 ]
Hejduk, Karel [3 ]
Bortlicek, Zbynek [3 ]
机构：
[1] Fac Med 1, Dept Oncol, Prague 2, Czech Republic
[2] Gen Fac Hosp Prague, Prague 2, Czech Republic
[3] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu165.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 0244
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [22] Bevacizumab (BV) plus chemotherapy (CT) as first-line treatment of patients with metastatic colorectal cancer (mCRC): First results from a large community-based observational cohort study in Germany
    Arnold, D.
    Kindler, M.
    Petersen, V.
    Tummes, D.
    Moelle, M.
    Schoeberl, C.
    Srock, S.
    Kutscheidt, A.
    Grothe, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : CP19 - U123
  • [23] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [24] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [25] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V
    ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
  • [27] ESTIMATION OF COSTS OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) WITH FOLFIRI, FOLFOX OR XELOX PLUS BEVACIZUMAB, IN FIVE MEXICAN INSTITUTIONS
    Calderillo, Ruiz G.
    VALUE IN HEALTH, 2011, 14 (07) : A539 - A539
  • [28] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [29] Bi-weekly XELOX (capecitabine/oxaliplatin) plus bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): PHOENIX trial
    Nagata, N.
    Okada, T.
    Okazaki, S.
    Sato, S.
    Kin, H.
    Nakamura, M.
    Kunieda, K.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S559 - S559
  • [30] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer Analysis of Multiple Methods
    Li, Shaotang
    Chi, Pan
    BIODRUGS, 2011, 25 (01) : 43 - 50
12345